AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00323427 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hearing aid services
Description: Standard VA audiological hearing aid dispensing services
Study NCT05530161 — intervention group
Intervention type: OTHER
Intervention: hypocalcemia
Description: hypocalcemia or normocalcemia
Study NCT02675244 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TV Annuloplasty
Description: TV Annuloplasty will be performed using standard surgical techniques
Study NCT02675244 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MVS
Description: MVS will be performed using standard surgical techniques
Study NCT03819166 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: with deep touch pressure application
Description: The deep touch pressure is applied by the weight loading devices, including but not limited to, weight blanket and weight vest.
Study NCT03819166 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: without deep touch pressure application
Description: The deep touch pressure will not be applied.
Study NCT01460888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 25mg tablets, oral. Commenced 3 days prior to radiotherapy and continuing until the last day of radiotherapy (36 days in total).
Study NCT01460888 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radical external beam radiotherapy, 50Gy in 25 fractions
Description: Radiotherapy to the oesophageal carcinoma. For patients receiving olaparib this is delivered as 50Gy in 25 daily fractions for 5 weeks (Monday-Friday only). For patients in the comparator arm (RT only) other total doses/ fractionation are permitted, according to local policy/ best standard care.
Study NCT01460888 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radical external beam radiotherapy, 50Gy in 25 fractions
Description: Radiotherapy to the oesophageal carcinoma. For patients receiving olaparib this is delivered as 50Gy in 25 daily fractions for 5 weeks (Monday-Friday only). For patients in the comparator arm (RT only) other total doses/ fractionation are permitted, according to local policy/ best standard care.
Study NCT02515825 — intervention group
Intervention type: DEVICE
Intervention: CADence
Study NCT00680017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-335 plus rosuvastatin
Description: ABT-335 45 mg plus rosuvastatin 5 mg for 8 weeks, then ABT-335 45 mg plus rosuvastatin 10 mg for 8 weeks
Study NCT00680017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin 5 mg for 8 weeks then rosuvastatin 10 mg for 8 weeks
Study NCT01509950 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Staples
Description: Staples for closure of cesarean section skin incision
Study NCT01509950 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prolene non-absorbable sutures
Description: Prolene non-absorbable sutures for closure of cesarean skin incision
Study NCT01509950 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Absorbable Sutures
Description: Absorbable sutures for closure of cesarean skin incision
Study NCT03763682 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genio(TM) bilateral hypoglossal nerve stimulation system
Description: Subjects will be consented, enrolled and eligibility criteria checked. If the subject is eligible, subject will proceed with the Genio(TM) implant implantation. Six (6) weeks after implantation, the implant will be activated and the subject will be assessed at 1 month plus 1 week, 2, 3, 4, 5 and 6 month(s) after implantation
Study NCT02542683 — intervention group
Intervention type: OTHER
Intervention: structured physical activity program
Description: a structured modest physical activity program
Study NCT00441298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir gel
Description: Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study product, 1% tenofovir gel, within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. They will be advised to use only two doses of gel in a 24-hour period.
Study NCT00441298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Universal HEC placebo)
Description: Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study product, placebo gel, within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. They will be advised to use only two doses of gel in a 24-hour period.
Study NCT00599469 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Far Infrared Radiation (5μm to 20μm wavelength)
Description: Far Infrared radiation for 30 to 40 minutes per treatment session.
Study NCT00323427 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hearing aid services
Description: Standard VA audiological hearing aid dispensing services
Study NCT03313804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitor
Description: Standard of care immune checkpoint inhibitor
Study NCT03313804 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Stereotactic Body Radiation Therapy OR Fractionated radiation therapy
Study NCT01225276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NewGam 10%
Description: Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam . The maintenance doses to be infused 7 times will be 2.0 g/kg every 21 (+/-4) days.
Study NCT00269113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 375mg/m2 iv monthly for 8 cycles
Study NCT01225276 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Loading dose at baseline (Week 0) in Placebo arm will be corresponding volume of an authorised 0.9% saline solution . The maintenance doses of the 0.9% saline solution to be infused 7 times will be given every 21 (+/-4) days.
Study NCT01225276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NewGam 10%
Description: Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam in all three NewGam treatment arms. The maintenance doses to be infused 7 times will be 1.0 g/kg every 21 (+/-4) days.
Study NCT01225276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NewGam 10%
Description: Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam in all three NewGam treatment arms. The maintenance doses to be infused 7 times will be 0.4 g/kg every 21 (+/-4) days.
Study NCT01931150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Dapsone 5% Gel
Study NCT00269113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy
Description: As prescribed
Study NCT00269113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard chemotherapy
Description: As prescribed
Study NCT01065506 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Treatment
Description: Cognitive Behavioral Treatment
Study NCT01065506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch
Description: Nicotine Patch
Study NCT01065506 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness Program
Description: Wellness Program
Study NCT01065506 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Aerobic Exercise
Study NCT02837796 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transobturator tape
Study NCT01931150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moisturizer
Description: The moisturizer for the study will be Vanicream™ Lite Lotion.
Study NCT01931150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral antibiotics
Study NCT03777085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2303
Description: 375mg/m2, iv q3w,6 cycles(each cycle is 3 weeks
Study NCT03777085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375mg/m2, iv q3w,6 cycles(each cycle is 3 weeks
Study NCT04593836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-menthol
Description: 20ml 0.8% L-menthol spray on the pyloric ring and observe the gastric peristalsis
Study NCT04593836 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20ml 0.8% placebo spray on the pyloric ring and observe the gastric peristalsis
Study NCT04673812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-fentanyl
Description: Bupivacaine-Fentanyl (BF) group (46 patients): will receive spinal anaesthesia with 12.5 mg hyperbaric Bupivacaine 0.5% (2.5 mL) plus 25 µg Fentanyl (0.5 mL) and (0.5 mL) normal saline added in the same syringe in a total volume of 3.5 mL.~Bupivacaine-Fentanyl-Naloxone (BFN) group (46 patients): will receive spinal anaesthesia with 12.5 mg hyperbaric Bupivacaine 0.5% (2.5 mL) plus 25 µg Fentanyl (0.5 mL) and 20 µg Naloxone (prepared in 0.5 mL normal saline) added in the same syringe in a total volume of 3.5 mL.
Study NCT01628393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Oral capsule taken once a day
Study NCT01628393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ozanimod
Description: Oral capsule taken once a day
Study NCT01628393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule taken once a day
Study NCT03742479 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane® Silk
Description: Injectable Hyaluronic Acid (HA)
Study NCT02012855 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT04503850 — intervention group
Intervention type: DRUG
Intervention: Mirabegron 50 MG
Description: Mirabegron 50 mg daily dose and follow Up of erectile function using international index of erectile function 5 scoring system
Study NCT04503850 — intervention group
Intervention type: DRUG
Intervention: Alpha Blockers
Description: Alpha blocker daily and evaluation of erectile function using international index of erectile function 5 scoring system
Study NCT02012855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet (meal type)
Study NCT01356498 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegloticase
Description: 8 mg intravenous infusion
Study NCT02931409 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optimal PEEP
Description: Optimal PEEP determined by Cstat during PEEP titration procedure.
Study NCT02931409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PEEP
Description: Lung protective mechanical ventilation applying a PEEP value of 6 cmH2O
Study NCT01890590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CyberKnife
Description: Stereotactic Body Radiation Therapy. 3 or 4 fractions of radiotherapy delivered by Cyberknife.
Study NCT03311581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol works by increasing GABA-mediated inhibitory tone in the CNS. Propofol decreases the rate of dissociation of the GABA from the receptor, thereby increasing the duration of the GABA-activated opening of the chloride channel with resulting hyperpolarization of cell membranes.
Study NCT03311581 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: sevoflurane inhalation 2\~4%
Study NCT00511628 — intervention group
Intervention type: DRUG
Intervention: Risperidone
Description: As prescribed
Study NCT02789436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L. reuteri Prodentis® lozenges
Description: Twice daily, for 28 days
Study NCT02789436 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo lozenges
Description: Twice daily, for 28 days
Study NCT05525130 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food supplement
Description: FagolitosPlus® is an authorized food supplement that contains hydroxycitric acid, vitamin complexes and ions.
Study NCT05525130 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo has a composition that makes the weight and organoleptic characteristics are identical to FagolitosPlus®.
Study NCT02038777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04449913
Description: PF-04449913 administered orally and continuously in 28 day cycles.
Study NCT02038777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose ARA-C (LDAC)
Description: Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
Study NCT02038777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Daunorubicin given using 60 mg/m2 for 3-days.
Study NCT02038777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 100 mg/m2 on days 1 through 7.
Study NCT02038777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine Combination Cohort; Azacitidine 75 mg/m2 for 7 days.
Study NCT02323399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: one of six initial treatments Phenylephrine Hydrochloride Injection (PHI) will be initially administered to approximately 50 subjects as an intravenous bolus (IV-B) at Low (1 μg/kg), Med (3 μg/kg), or High (5 μg/kg) level; PHI will be initially administered to approximately 50 subjects as a continuous intravenous infusion (IV-I) at Low (0.25 μg/kg/min), Med (0.75 μg/kg/min), or High (1.25 μg/kg/min) level\]; each initial treatment group will have two PK sampling schedules.
Study NCT02219217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir, Elvitegravir and Cobicistat
Study NCT02425436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo Biloba Extract
Study NCT02425436 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03578380 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Lymphovenous anastomosis
Study NCT02651779 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open reduction and internal plate fixation
Study NCT02651779 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Closed reduction and plasterimmobilisation
Study NCT04197427 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Oral Rinse
Description: Experimental Oral Rinse is a proprietary formulation of GRAS ingredients
Study NCT04197427 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo formulation without the active ingredients
Study NCT03578380 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression and drainage therapy
Description: Treatment with compression stockings and manual drainage (massage therapy)
Study NCT00071799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine was injected subcutaneously (SC) at an initial dose of 75mg/m\^2/day for 7 days. The 7-day dosing was repeated every 28 days with dose adjustment based on predefined hematology and renal laboratory results. Number of cycles: Azacitidine treatment was to be continued until the end of the study unless treatment was discontinued due to unacceptable toxicity, relapse after complete or partial response, transformation to AML or disease progression.
Study NCT00071799 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physician Choice
Description: Physician Choice was one of three options:~* Best supportive care (BSC) alone,~* Low-dose cytarabine subcutaneously for 14 days every 28 to 42 days, or~* Standard chemotherapy administered for induction as a continuous intravenous infusion of cytarabine over 7 days plus an anthracycline (daunorubicin, idarubicin, or mitoxantrone) on Days 1, 2, and 3; and, for those eligible, 1 or 2 consolidation cycles administered as continuous intravenous infusions of cytarabine for 3 to 7 days with the same anthracycline that was used at induction on Days 1 and 2 (each cycle between 28 to 70 days from the start of the previous cycle).~All three options included best supportive care
Study NCT03661372 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Robot
Description: Use of a telesimulation robot using contextual interview format.
Study NCT03661372 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face
Description: Use of face-to-face patient interview using contextual interview format.
Study NCT01692834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sandimmune® Injection
Study NCT01692834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NeuroSTAT®
Study NCT01155960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
Study NCT01155960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
Study NCT02038777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDAC
Description: Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
Study NCT01432106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskerin/Valsartan and Rampiril
Description: Patients will start on low dose Ramipril 10 mg or Valturna 150/160 at visit 2, and up-titrate to target dose of Ramipril 20 mg or Valturna 300/320 at visit 3. At visit 5, the addition of Hydrochlorothiazide (HCTZ) or amlodipine will be allowed to achieve the SBP target of \< 140 mmHg. High dose will then be maintained throughout the remainder of the study. In case of symptoms of low blood pressures, the study medication may be decreased to the low dose.~(However, all non-study medication will be manipulated, initially.)
Study NCT00391898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa/entacapone
Description: Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa/entacapone was available in 2 oral dosage forms: 100/25/200 or 150/37.5/200 mg encapsulated tablets.
Study NCT00391898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa/carbidopa
Description: Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa was available in 2 oral dosage forms: One or one and one-half 100/25 mg encapsulated tablets.
Study NCT00033423 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT04569396 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemistry analysis
Description: Biochemistry analysis of liver parameters were analyzed among the study subjects before and after the surgery.
Study NCT04569396 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: NAFLD fibrosis score
Description: NAFLD fibrosis score was determined among the study subjects before and after the surgery.
Study NCT04569396 — intervention group
Intervention type: OTHER
Intervention: BMI measurement
Description: BMI was measured among the study subjects before and after the surgery.
Study NCT04569396 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fibrosis 4 Index
Description: Fibrosis 4 Index was determined among the study subjects before and after the surgery.
Study NCT04569396 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fatty Liver Index
Description: Fatty Liver Index was determined among the study subjects before and after the surgery.
Study NCT01030653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole low dose
Description: Voriconazole 400 mg po x 2 doses (loading dose)then 200 mg po twice daily x 7 doses
Study NCT01030653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole high dose
Description: Voriconazole 400 mg po x 2 doses (loading dose)then 300 mg po twice daily x 7 doses
Study NCT03240237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optimizer SMART
Description: Cardiac Contractility Modulation
Study NCT00977379 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: WBRT
Description: 3000 cGy WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction).
Study NCT00977379 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WBRT
Description: 3000 cGy WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction).
Study NCT00977379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825 mg/m\^2 orally twice daily, Days 1-14 of a 21 day cycle for 1 cycle followed by 1000 mg/m\^2 orally twice daily Days 1-14 every 21 days starting with Cycle 2.
Study NCT00033423 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Study NCT01078194 — intervention group
Intervention type: DEVICE
Intervention: Secondary Bypass Banding (adjustable A.M.I. Soft Gastric Band)
Description: Secondary Placement of the A.M.I. Soft Gastric Band for laparoscopic bypass banding
Study NCT02452216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Undergo ferumoxytol-enhanced MRI